Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 85 peer-reviewed journal articles Updated
Orthopedic Oncology

Getting Your Bearings with Chondrosarcoma

At a Glance

Chondrosarcoma is a rare bone cancer where surgery is the primary and most effective treatment. The tumor's grade is the most important factor in determining the treatment plan and outlook. Low-grade tumors have excellent outcomes, and expert review by a specialized bone pathologist is crucial.

Receiving a diagnosis of chondrosarcoma (a type of cancer that arises in the cartilage-producing cells of the bone) can feel like your world has suddenly shifted [1]. It is natural to feel overwhelmed, but finding your footing begins with understanding that while this is a rare disease, the path forward is well-mapped by experts [2][3].

Understanding the Rarity

Chondrosarcoma is rare, affecting approximately 1 in every 200,000 people each year [4][5]. Despite its rarity, it is actually the second most common primary bone cancer, accounting for about 10% to 20% of all malignant bone tumors [6][3]. Because it is uncommon, it is vital to be treated at a specialized center (see Building Your Care Team) where doctors have deep experience with this specific disease [7].

Three Stabilizing Facts for Your Journey

When everything feels uncertain, these three evidence-based facts can help ground your perspective:

  1. Surgery is the Primary Solution: Unlike many other cancers that rely heavily on systemic treatments, the “gold standard” for most chondrosarcomas is surgical removal [2][8]. Because most of these tumors grow slowly and are resistant to traditional chemotherapy and radiation, a successful surgery with clear margins (a layer of healthy tissue removed around the tumor) is often the most critical step toward a cure [9][10]. Learn more in Treatment Strategy.
  2. Grade Dictates Everything: The most important word in your pathology report is “Grade.” This tells you how aggressive the cells look under a microscope and is the single biggest factor in determining your treatment and outlook [11][12].
  3. Low-Grade Tumors Have Excellent Outlooks: Many chondrosarcomas are low-grade. In the arms and legs, these are often called Atypical Cartilaginous Tumors (ACT) [13]. These tumors very rarely spread to other parts of the body and are often managed with less invasive surgical techniques [14][15].

What Research Agrees On

The international medical community reaches a strong consensus on several key points regarding your care:

01

Decoding Your Pathology: Grades and Subtypes

Learn how to read your chondrosarcoma pathology report. Understand tumor grades (1-3), subtypes like dedifferentiated, and what IDH1/IDH2 mutations mean.

02

Survivorship: Navigating Long-Term Monitoring

Learn what to expect during chondrosarcoma survivorship. Understand long-term monitoring schedules, lung surveillance, the ten-year rule, and scan anxiety.

While this diagnosis is a significant life event, your care team’s goal is to move you from the “diagnosis phase” into a “management phase” as quickly and safely as possible [21].

Common questions in this guide

What is the most effective treatment for chondrosarcoma?
Surgery is the primary and most effective treatment for chondrosarcoma. Most of these tumors are resistant to traditional chemotherapy and radiation, making complete surgical removal with clear margins the most critical step toward a cure.
Why is the grade of my chondrosarcoma so important?
The grade of your tumor tells doctors how aggressive the cancer cells appear under a microscope. This grade is the single most important factor in determining your specific treatment plan and your long-term outlook.
What is an atypical cartilaginous tumor (ACT)?
An atypical cartilaginous tumor, or ACT, is a term often used for low-grade chondrosarcomas located in the arms and legs. These tumors rarely spread to other parts of the body and can often be managed with less invasive surgical procedures.
Will I need chemotherapy or radiation for chondrosarcoma?
In most cases, conventional chondrosarcoma does not respond well to standard chemotherapy or radiation. These treatments are usually only used for specific, rare subtypes of the disease or in situations where surgery is not possible.
Why do I need my biopsy reviewed by a specialized bone pathologist?
Chondrosarcoma can look very similar to non-cancerous bone growths under a microscope. Having a dedicated bone pathologist review your biopsy is crucial to ensure you receive an accurate diagnosis and correct tumor grade, which dictates your entire treatment plan.

Get notified when new evidence is published on Chondrosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Chondrosarcoma of the spine-a case report.

    Simon S, Resch H, Lomoschitz F, et al.

    Wiener medizinische Wochenschrift (1946) 2023; (173(13-14)):334-338 doi:10.1007/s10354-021-00897-9.

    PMID: 35119543
  2. 2

    Effect of surgery and radiotherapy on overall survival in patients with chondrosarcoma: A SEER-based study.

    Wang M, Song Y, Liu S, Sun W

    Journal of orthopaedic surgery (Hong Kong) 2022; (30(1)):10225536221086319 doi:10.1177/10225536221086319.

    PMID: 35349776
  3. 3

    The role of imaging in differentiating low-grade and high-grade central chondral tumours.

    Sharif B, Lindsay D, Saifuddin A

    European journal of radiology 2021; (137()):109579 doi:10.1016/j.ejrad.2021.109579.

    PMID: 33578088
  4. 4

    Chondrosarcoma of the spine: a narrative review.

    Pennington Z, Ehresman J, Pittman PD, et al.

    The spine journal : official journal of the North American Spine Society 2021; (21(12)):2078-2096 doi:10.1016/j.spinee.2021.04.021.

    PMID: 33971325
  5. 5

    Conventional chondrosarcoma in the right hand with the invasion of the pisiform and the hamate bones - case report.

    Pop DL, Motoc AGM, Hărăguş HG, et al.

    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2017; (58(1)):271-275.

    PMID: 28523331
  6. 6

    Primary juxtacortical chondrosarcoma of mandibular symphysis: Unique and rare case report.

    Bakyalakshmi K, Jayachandran S, Sureshkumar M

    Journal of cancer research and therapeutics 2015; (11(4)):1025 doi:10.4103/0973-1482.148683.

    PMID: 26881593
  7. 7

    A case of chondrosarcoma with costovertebral location in the posterior mediastinum: Resection and stabilization.

    Mutlu F, Akçalı Ö, Şanlı A

    Asian cardiovascular & thoracic annals 2025; (33(1)):59-61 doi:10.1177/02184923241311937.

    PMID: 39901477
  8. 8

    Is the Width of a Surgical Margin Associated with the Outcome of Disease in Patients with Peripheral Chondrosarcoma of the Pelvis? A Multicenter Study.

    Tsuda Y, Evans S, Stevenson JD, et al.

    Clinical orthopaedics and related research 2019; (477(11)):2432-2440 doi:10.1097/CORR.0000000000000926.

    PMID: 31453886
  9. 9

    Rare Case of Scapular Body Chondrosarcoma Treated With Limb-Salvage Partial Scapulectomy: A Case Report Highlighting Surgical Technique.

    Alfadil S, Alarnous FM, Alsuwayeh F, et al.

    Cureus 2024; (16(10)):e71519 doi:10.7759/cureus.71519.

    PMID: 39553041
  10. 10

    Precision medicine for adjuvant chemotherapy of resected colorectal cancer.

    Miyamoto Y, Hiyoshi Y, Sawayama H, et al.

    Annals of gastroenterological surgery 2020; (4(6)):635-645 doi:10.1002/ags3.12397.

    PMID: 33319153
  11. 11

    A new scoring system for the grading of conventional chondrosarcoma: Its clinicopathological significance.

    Susuki Y, Yamada Y, Ito Y, et al.

    Pathology, research and practice 2022; (238()):154125 doi:10.1016/j.prp.2022.154125.

    PMID: 36174441
  12. 12

    Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

    Song K, Shi X, Liang X, et al.

    International orthopaedics 2018; (42(12)):2941-2948 doi:10.1007/s00264-018-3942-7.

    PMID: 29681020
  13. 13

    Chondrosarcoma.

    Weinschenk RC, Wang WL, Lewis VO

    The Journal of the American Academy of Orthopaedic Surgeons 2021; (29(13)):553-562 doi:10.5435/JAAOS-D-20-01188.

    PMID: 33595238
  14. 14

    Long-term follow up of patients with low-grade chondrosarcoma in the appendicular skeleton treated by extended curettage and liquid nitrogen.

    El Masry AM, Azmy SI, Mustafa MAR, Abdel Aal MM

    Orthopaedics & traumatology, surgery & research : OTSR 2023; (109(3)):103410 doi:10.1016/j.otsr.2022.103410.

    PMID: 36116704
  15. 15

    Case Report: Reconstruction After Anterior Pubic Hemipelvectomy.

    Murphy B, Thillainadesan T, Robinson K, et al.

    Frontiers in surgery 2021; (8()):585600 doi:10.3389/fsurg.2021.585600.

    PMID: 34095198
  16. 16

    Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.

    Joseph NM, McGill KC, Horvai AE

    The American journal of surgical pathology 2021; (45(6)):812-819 doi:10.1097/PAS.0000000000001626.

    PMID: 33239505
  17. 17

    Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.

    Ouyang Z, Wang S, Zeng M, et al.

    Cell communication and signaling : CCS 2019; (17(1)):17 doi:10.1186/s12964-019-0327-5.

    PMID: 30808351
  18. 18

    Risk calculator for long-term survival prediction of spinal chordoma versus chondrosarcoma: a nationwide analysis.

    Ghaith AK, Yang X, Al-Mistarehi AH, et al.

    Journal of neuro-oncology 2025; (174(2)):511-525 doi:10.1007/s11060-025-05063-4.

    PMID: 40295452
  19. 19

    Impact of proton vs. photon radiotherapy on overall survival in the management of spinal chondrosarcoma and mortality risk prediction: A nationwide analysis.

    Ghaith AK, Yang X, Khalilullah T, et al.

    Neuro-oncology advances 2026; (8(1)):vdaf240 doi:10.1093/noajnl/vdaf240.

    PMID: 41552408
  20. 20

    Surgical resection of late extrahepatic metastasis of hepatocellular carcinoma 11 years after initial diagnosis: case report and literature review.

    Baz C, Nudotor R, Ian B, et al.

    Journal of surgical case reports 2024; (2024(10)):rjae632 doi:10.1093/jscr/rjae632.

    PMID: 39380794
  21. 21

    A population-based analysis of primary colonic lymphoma: Patterns of care and outcomes.

    Welton LL, Kohn JF, Troester AM, et al.

    Surgery 2025; (182()):109346 doi:10.1016/j.surg.2025.109346.

    PMID: 40158384

This page provides an introductory overview of chondrosarcoma for educational purposes only. Always consult with an orthopedic oncologist and your specialized care team for personalized medical advice.